LAUSR

Ocular ischemic syndrome (OIS) is caused by ocular hypoperfusion because of stenosis or occlusion of the carotid arteries.1 Retinal and choroidal ischemia is closely associated with vision loss, which is unfortunately acute and irreversible. Excessive production of vascular endothelial growth factor (VEGF), caused by ischemic condition may lead to the development of secondary glaucoma. However, no proven treatment to resolve this vicious cycle of ischemia is available. Vascular endothelial growth factor inhibitors have been used to treat macular edema2 or neovascular glaucoma3 complicated by OIS, but the safety and efficacy of the treatment have not been fully verified. This photo Fig. 1. Slit-lamp photographs (left column) and wide-field fundus photographs (right column) before (A) and 1 week after (B) an intracameral bevacizumab injection in the eye with OIS demonstrating a significant regression of neovascularization of the iris and disk.